Sulforaphane Side Effects & Safety: Human Data by Dose and Form

Sulforaphane side effects cannot be summarized with one universal list or one incidence rate. Human studies have tested foods, broccoli-sprout beverages, glucoraphanin-rich extracts, glucoraphanin-plus-myrosinase systems and stabilized direct sulforaphane at very different exposures.

The safest way to read the literature is therefore by formulation, delivered dose, duration and population rather than assuming that every product labelled “sulforaphane” has the same tolerability profile.

Safety at a glance

What did the earliest Phase I safety study find?

A randomized double-blind Phase I study enrolled 12 healthy adults and tested broccoli sprout preparations delivering glucosinolates or isothiocyanates every eight hours for seven days. Investigators monitored hematology, clinical chemistry, liver-related markers, thyroid-related measures and adverse effects.

No significant or consistent toxicities were attributed to the tested preparations.^[2]

That is reassuring, but it is a 12-person, one-week study. It cannot answer what happens after years of daily use.

Higher direct sulforaphane exposure changes the safety picture

A 2025 Phase I randomized placebo-controlled study tested enteric-coated stabilized sulforaphane (SFX-01) in 24 healthy men for seven days. Eighteen participants received active treatment at 46.2 mg/day, 46.2 mg twice daily or 92.4 mg/day of sulforaphane.^[3]

Seventeen of the 18 active-treatment participants reported treatment-emergent adverse events. The most common were gastrointestinal—including abdominal discomfort, nausea and vomiting—and most were mild and transient.

This does not mean 94% of ordinary sulforaphane-supplement users will experience side effects. It means a pharmacologic direct-sulforaphane formulation at those defined doses produced frequent adverse-event reporting in a small Phase I trial. Food exposure and precursor-based supplements can yield very different systemic exposure.

Can sulforaphane affect the thyroid?

Cruciferous vegetables are often discussed in thyroid conversations because glucosinolates can generate multiple biologically active compounds. The best direct human safety analysis in this cluster is more reassuring than the internet discussion often suggests.

In a 12-week randomized-trial analysis of 45 women consuming a sulforaphane- and glucoraphanin-rich broccoli sprout beverage, TSH, free T4, thyroglobulin and thyroid-autoimmunity status did not significantly worsen.^[1]

That result applies to the tested intervention and duration. It does not prove that every concentrated cruciferous supplement is harmless in every thyroid disorder.

What gastrointestinal side effects should you watch for?

Across studies and products, gastrointestinal symptoms are the most plausible recurring issue. Depending on formulation and exposure, trials may report:

• abdominal discomfort;
• nausea;
• bloating or gas;
• changes in bowel habits;
• vomiting at higher direct exposures.

The literature does not support one reliable percentage across all products because the administered compounds are not equivalent. A broccoli-sprout beverage, a glucoraphanin precursor and 92.4 mg/day of stabilized direct sulforaphane are not the same exposure.

If symptoms are severe, persistent or clearly dose-related, the sensible response is to stop or reduce the product and review it—not to reinterpret symptoms as a beneficial “detox reaction.”

Does formulation affect safety?

Yes, because formulation affects systemic exposure. Human pharmacokinetic studies repeatedly show that the same apparent broccoli-derived dose can produce several-fold differences in sulforaphane delivery.

Raw broccoli produced estimated bioavailability of about 37% versus 3.4% after cooked broccoli in a small crossover study.^[4] Adding active mustard-seed myrosinase increased bioavailability from 18.6% to 39.8% in a 2026 crossover trial.^[5]

That means safety interpretation should follow the delivered exposure, not simply the label's total broccoli milligrams.

Sulforaphane and medication interactions

There is not enough human evidence to publish a confident, comprehensive drug-interaction list. Sulforaphane can influence xenobiotic-metabolism and cellular stress-response pathways, but mechanistic plausibility alone does not prove that a clinically important interaction occurs at supplement doses.

A more defensible approach is increased caution when someone:

• takes drugs with a narrow therapeutic window;
• uses multiple medications whose doses are actively being adjusted;
• is receiving chemotherapy, radiotherapy or other active oncology treatment;
• has advanced kidney or liver disease; or
• uses several concentrated supplements targeting overlapping pathways.

Those situations deserve clinician or pharmacist review rather than internet interaction charts built mainly from cell studies.

What about kidney disease?

A 2026 multicenter randomized trial studied people with type 2 diabetes and stage 3b–4 chronic kidney disease. The broccoli sprout extract did not significantly improve glycemic endpoints.^[6]

The existence of that study expands the evidence base into a medically complex group; it does not establish routine self-supplementation as safe for all people with CKD. Kidney disease changes medication handling, nutrition and clinical risk.

Pregnancy and breastfeeding

Eating ordinary cruciferous vegetables as food is not equivalent to concentrated supplemental exposure. High-quality supplementation data in pregnancy and breastfeeding are inadequate to define a safe routine dose. A conservative approach is to use clinician guidance before taking concentrated products.

Children and adolescents

Sulforaphane has been studied in pediatric and adolescent autism research, but disease-specific trials do not define a general wellness dose or long-term safety profile for healthy children.^[7]

Active cancer treatment

Sulforaphane has substantial mechanistic and early clinical oncology research, but that is exactly why self-adding a concentrated product during treatment deserves caution. A 2023 systematic review found heterogeneous randomized cancer data rather than established therapeutic efficacy.^[8]

Do not use a supplement to replace cancer therapy or assume a mechanistic anticancer pathway means it is automatically beneficial alongside every treatment regimen.

How to reduce avoidable risk

1. Know what the product actually supplies. Direct sulforaphane, glucoraphanin plus myrosinase and generic broccoli extract can produce different exposure.
2. Start with the product's tested or labelled dose rather than extrapolating from unrelated trials.
3. Do not chase the highest label number.
4. Do not interpret persistent adverse symptoms as evidence that “detox” is working.
5. Use clinical review for pregnancy, children, active medical treatment, major organ disease or complex medication regimens.

Bottom line

The human safety record is broadly reassuring for many short- and medium-term broccoli-sprout and precursor-based interventions, but sulforaphane safety is dose- and formulation-dependent. Higher direct exposure can produce substantially more gastrointestinal symptoms, and long-term daily safety remains less well defined than short-term tolerability.

Use the dosage guide to understand exposure, and the supplement guide to decode product labels before assuming two products have equivalent safety.